Interchangeable Biosimilar Approval: FDA Greenl...

By João L. Carapinha

November 17, 2025

FDA Grants First Interchangeable Biosimilar Approval for HER2-Positive Breast Cancer Treatment The U.S. Food and Drug Administration (FDA...
HIV Therapy Advancements: Promising Results from Bictegravir/Lenacapavir Comb...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
Weight Loss: Advances in Hormone-Based Obesity Treatments
Beta-Blockers in Heart Attack Recovery: Reevaluating Their Role Based on Rece...
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Red...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Effici...
Antidepressant Side Effects: New Insights on Cardiometabolic Health Risks
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Center...
Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for Ig...